Pricing Log in Create free account

Avalo Therapeutics, Inc. (AVTX) vs Contineum Therapeutics, Inc. (CTNM)

Avalo Therapeutics, Inc. and Contineum Therapeutics, Inc. are both Biotechnology companies. Avalo Therapeutics, Inc. and Contineum Therapeutics, Inc. are of similar size ($355.6M and $345.9M). Across the 9 metrics below, Contineum Therapeutics, Inc. leads on 5 and Avalo Therapeutics, Inc. on 4.

Valuation

Metric AVTX CTNM Biotechnology median
P/E n/m n/m 10.60
P/S 243.01 n/m 9.40
P/B 0.68 1.47 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.94 n/m 0.66
EV/Sales (68.78) n/m 9.02
Earnings yield (68.36%) (18.76%) (32.88%)
Free cash flow yield (45.92%) (14.44%) (23.13%)

Profitability

Metric AVTX CTNM Biotechnology median
Gross margin 64.72% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (36.27%) (29.80%) (51.96%)
Return on assets (32.50%) (28.34%) (46.06%)
Return on invested capital (118.21%) (4,845.62%) 0.00%

Growth

Metric AVTX CTNM Biotechnology median
Revenue growth (TTM) (92.65%) — 6.76%
EPS growth (last fiscal year) 72.07% 0.46% 29.88%
Revenue growth, 5-year CAGR (61.19%) — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AVTX CTNM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 19.31 31.11 4.97
Net debt to EBITDA 1.36 3.88 1.01

Dividend

Metric AVTX CTNM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AVTX CTNM Biotechnology median
Market cap 355.56m 345.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack